Abstract

Schizophrenia poses a significant economic burden on the healthcare system as well as it has a significant impact on society at large. Reasons for such a high economic burden of schizophrenia include the frequent relapses and hospitalizations occurring in this disorder. We analyze the effectiveness of long-acting injectable antipsychotics (LAIs) compared to oral medications, in terms of "clinical process management" in a sample of patients with a diagnosis of schizophrenia spectrum disorder treated in community mental health centers. An observational, retrospective, mirror-image study was carried out to evaluate the effectiveness of LAIs compared to oral medications in terms of number of hospitalizations, emergency visits and planned visits on a 10-year period (from July 2007 to June 2017). Differences between first and second generation LAIs were also explored. Our findings show that hospitalization and emergency visits are significantly decreased with the use of LAIs, while planned visits are increased in patients treated with LAIs. Our results suggest that LAIs, in particular, second generation ones, reduce hospitalization rates and emergency visits, improving the economic burden of schizophrenia. Therefore, LAIs should be considered a cost-effective treatment in the management of schizophrenia under routine conditions.

Highlights

  • Schizophrenia is a severe, chronic, often recurring mental disorder affecting 1% of the general population, and it is associated with a relevant long-term impact on patients’ social and occupational functioning

  • long-acting injectable antipsychotics (LAIs) generation seems to have an effect on hospitalization rates, emergency rates, and total number of emergency visits; it has a lower effect on total number of Characteristics Gender, n (%) Male Female Age, mean ±SD Years Educational level, mean ±SD Years of scholarization Diagnosis, n (%) Schizophrenia Schizoaffective disorder Other schizophrenia spectrum Illness duration, mean ±SD Years

  • We considered the number of hospitalizations, the number of emergency and planned visits one year before and after the change from oral to LAI antipsychotics

Read more

Summary

Introduction

Schizophrenia is a severe, chronic, often recurring mental disorder affecting 1% of the general population, and it is associated with a relevant long-term impact on patients’ social and occupational functioning. It is treated with a combination of medical, psychological and psychosocial interventions, with varying degrees of success. Improving the “real life” management of schizophrenia spectrum disorders by LAI antipsychotics

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call